Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature

Table 1 Baseline general information and clinical and laboratory characteristics

Characteristics
Age in yr	44
Sex	Male
Body weight in kg	60
Hb in g/L	49
SI in μmol/L	24.0
TIBC in μmol/L	51.6
TSAT, %	46.51
SF in ng/mL	656.03
iPTH in pg/mL	385
Dialysis method: hemodialysis/peritoneal dialysis	Hemodialysis
Duration of dialysis in yr	1.33
Dose of rhEPO injection in IU	6000
Frequency of rhEPO injection as times/wk	3
Blood pressure
Systolic in mmHg	157
Diastolic in mmHg	96
CRP in mg/L	4.61
Blood lipids
TC in mmol/L	3.76
TGs in mmol/L	5.19
LDL-C in mmol/L	0.74
HDL-C in mmol/L	2.43

CRP: C-reactive protein; EPO: Endogenous erythropoietin; Hb: Hemoglobin; HDL-C: High-density lipoprotein cholesterol; iPTH: Intact parathyroid hormone; LDL-C: Low-density lipoprotein cholesterol; rhEPO: recombinant human erythropoietin; SF: Serum ferritin; SI: Serum iron; TC: Total cholesterol; TG: Triglyceride; TIBC: Total iron-binding capacity; TSAT: Transferrin saturation.

Table 2 Changes in iron metabolism indices after oral administration of Roxadustat

		Date
Index	Baseline	Oct 2019	Nov 2019	Dec 2019	Jan 2020	Feb 2020	Mar 2020	Apr 2020	May 2020
SI in μmol/L	24.00	47.00	40.90	24.70	51.40	18.60	43.5	24.4	36.5
TIBC in μmol/L	51.6	50.7	55.2	54.3	54.9	63.9	63.5	69.9	55.2
TAST, %	46.51	92.70	74.09	45.49	93.62	29.11	68.5	34.91	66.12
SF in ng/mL	656.03	724.84	798.02	574.53	432.47	420.11	337.21	570.57	320.16

SF: Serum ferritin; SI: Serum iron; TIBC: Total iron-binding capacity; TSAT: Transferrin saturation.